In 14,194 patients after acute coronary syndrome, adding milvexian 25 mg twice daily to antiplatelet therapy did not reduce CV death, MI or ischaemic stroke vs placebo (5.4% vs 5.1%; HR 1.05, 95% CI 0.91–1.21). Trial stopped for futility; severe bleeding 0.3% in both groups.
RCTn = 14,194
Gibson et al. Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event